LivaNova PLC

LIVN - CIK 0001639691

Market cap$4.29 B

Rank#1514

SEC filings917

LivaNova PLC trades as LIVN and has a market capitalization of $4.29 B, making it the #1514 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.39B, up 10.7% from the prior year and net income of -$242.50M. This page tracks LivaNova PLC through 917 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$1.39BFY 2025

Net income (latest FY)-$242.50MFY 2025

Operating cash flow (latest FY)$254.34MFY 2025

Total assets (latest FY)$2.61BFY 2025

Gross margin67.7%latest FY

Net margin-17.5%latest FY

Financial performance

Over the last 9 fiscal years LivaNova PLC's revenue grew from $964.86M to $1.39B, a compound annual growth rate of 4.1%. Net profit margin compressed from -6.5% to -17.5% over the same period - every figure below comes from the company's audited annual filings.

LIVN annual revenueView details

Key statistics

Market cap: $4.29 B
Share price (derived)market cap / shares outstanding: $78.19
EPS (diluted)FY 2025: $-4.45
Shares outstandingas of 2026-04-29: 0.05B
Total equityas of 2026-03-31: $1.21B
Return on equity: -20.0%
Long-term debtas of 2026-03-31: $285.28M
Cash & equivalentsas of 2026-03-31: $539.71M

Latest filings

Filing	Type	Filed
Insider sale notice	144	2026-05-26
IRANNOTICE	-	2026-05-06
Quarterly report	10-Q	2026-05-06
Major company event	8-K	2026-05-06
SCHEDULE 13G/A	-	2026-04-30
Annual report to shareholders	ARS	2026-04-29
Proxy materials	DEFA14A	2026-04-29
Proxy statement	DEF 14A	2026-04-29

Browse the full filing history (917 filings)

Recent press releases

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit2026-05-21
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit | LivaNova PLC
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June2026-05-19
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June | LivaNova PLC
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance2026-05-06
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance | LivaNova PLC
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea2026-04-20
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea | LivaNova PLC
LivaNova to Announce First-Quarter 2026 Results2026-03-25
LivaNova to Announce First-Quarter 2026 Results | LivaNova PLC

Similar companies

The largest companies sharing LivaNova PLC's SEC industry classification (electromedical & electrotherapeutic apparatus).

MDTMedtronic plc$103.24 B LIVN vs MDT

MASIMasimo Corporation$9.43 B LIVN vs MASI

ITGRInteger Holdings Corporation$3.13 B LIVN vs ITGR

TMDXTransMedics Group, Inc.$2.59 B LIVN vs TMDX

AXGNAxogen, Inc.$2.19 B LIVN vs AXGN

Frequently asked questions

What is LivaNova PLC's market cap?

LivaNova PLC (LIVN) has a market capitalization of $4.29 B as of 2026-06-10, ranking #1514 among US-listed companies.

How much revenue does LivaNova PLC make?

LivaNova PLC reported revenue of $1.39B for fiscal year 2025, an increase of 10.7% year over year.

Is LivaNova PLC profitable?

In its latest fiscal year LivaNova PLC reported a net loss of $242.50M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.